Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493144 | 0.91 | CYP2D6 (0.54) | OPRL1CYP3A4HSD17B10POLBSIGMAR1 | |
| SCHEMBL1314774 | 0.90 | OPRL1 (0.63) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| SCHEMBL25600026 | 0.84 | OPRL1 (0.55) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| SCHEMBL19322400 | 0.81 | OPRL1 (0.53) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| SCHEMBL728381 | 0.81 | OPRL1 (0.59) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| Hydrochloric Acid SCHEMBL9179035 | 0.80 | POLB (0.54) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| SCHEMBL28641509 | 0.80 | OPRL1 (0.51) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| SCHEMBL9174263 | 0.80 | OPRL1 (0.51) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| Hydrochloric Acid SCHEMBL9718148 | 0.80 | POLB (0.54) | OPRL1CYP3A4HSD17B10POLBKMT2A | |
| SCHEMBL3222218 | 0.80 | OPRL1 (0.51) | OPRL1CYP3A4HSD17B10POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| CN-111848577-B | N- (hetero) aryl-substituted heterocyclic derivatives useful in the treatment of diseases or conditions associated with the central nervous system | 克罗诺斯治疗有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3194385-B3 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | CHRONOS THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| US-5453422-A | Animal growth promoters | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-26 | — | — | US | disclosed |
| US-5284842-A | Active against gramnegative bacteria | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5173484-A | Animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-22 | — | — | US | disclosed |
| EP-0326916-A2 | Quinolone- and naphthyridone-carboxylic acid derivatives, method for their preparation and antibacterial agents and food additives containing them | BAYER AG (DE) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | OPRL1 1164/4885CYP3A4 1188/4885HSD17B10 2598/4885 |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | OPRL1 2919/4885CYP3A4 1408/4885HSD17B10 968/4885 |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | OPRL1 4305/4885CYP3A4 187/4885HSD17B10 636/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | OPRL1 1166/4885CYP3A4 1134/4885HSD17B10 2568/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | OPRL1 4305/4885CYP3A4 187/4885HSD17B10 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.